You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Systemic Therapy for Metastatic Urothelial Cancer: An Endorsement of a Portion of the European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancer

ID: GL END 3-24 aoû 2022
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
S. Hotte, J. Brown, C. Canil, A. Lalani, S. Sridhar, the Systemic Therapy for Metastatic Urothelial Cancer Guideline Development Group

Guideline Objective:

The objectives of this guideline are to assess the optimal systemic therapy for metastatic urothelial cancer. Our recommendations are based on a portion of the 2021 European Association of Urology (EAU) guideline on Muscle-Invasive and Metastatic Bladder Cancer https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.

Patient Population:

The target population is patients with metastatic urothelial cancer.

Intended Guideline Users:

The intended users of this guideline are clinicians involved in the care of patients with metastatic urothelial cancer.

pdf download Full Report (PDF) (333.55 Ko)